Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm

J Allergy Clin Immunol Pract. 2019 Mar;7(3):1076-1077. doi: 10.1016/j.jaip.2018.07.045. Epub 2018 Aug 29.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Aspirin / administration & dosage
  • Asthma, Aspirin-Induced / complications
  • Asthma, Aspirin-Induced / drug therapy*
  • Coronary Vasospasm / complications
  • Coronary Vasospasm / drug therapy*
  • Desensitization, Immunologic
  • Female
  • Humans
  • Interleukin-5 / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal, Humanized
  • IL5 protein, human
  • Interleukin-5
  • mepolizumab
  • Aspirin